GB-261

N/A

Report date: 2026/04/17 20:02:02

Base Information

Drug NameGB-261
Drug Alias NameGB-261CND261CND-261
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsT cell surface glycoprotein CD3 modulators +[4] 
TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD20
Therapy Area/IndicationsScleroderma, SystemicArthritis, RheumatoidLymphoma, B-Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUkraineAustraliaGeorgia +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGenor Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCandid Therapeutics IncTRC 2004 IncGenor Biopharma Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicArthritis, RheumatoidLymphoma, B-Cell +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A